ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2026
Asperginase-based chemotherapy regimen for acute lymphoblastic leukemia: A cohort study with promising outcomes on adults.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells. Asparaginase-based regimens are highly effective in pediatric ALL, but concerns over toxicity have limited their use in adults. This study evaluates the incidence of adverse events following asparaginase treatment in the adult ALL population. Materials and Methods: In this retrospective cohort study, we assessed drug-related adverse events among 67 adults with ALL treated with either a hyper-central vascular access device (CVAD) ( Results: Age-adjusted analysis showed the risk of thrombosis was significantly higher in the asparaginase group compared to hyper-CVAD (odds ratio [OR] = 17.9, 95% confidence interval [CI]: 1.69-2512, Conclusion: Asparaginase use in adults with ALL was associated with fewer overall adverse events, specifically lower infection risks, compared to hyper-CVAD. However, it significantly increased the risk of thrombosis, an effect driven primarily by the PEG-asparaginase formulation. While L-asparaginase appeared more favorable, the small sample size limits generalizability. These findings indicate that asparaginase remains a viable option for adults, but requires vigilant monitoring and prophylaxis for thrombotic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.